University of Miami Sylvester Comprehensive Cancer Center

 

University of Miami's 2nd Biennial Miami Leukemia Symposium
J

Advances in the CLL Frontline Therapy: BTK Inhibitors vs. Chemoimmunotherapy, Venetoclax vs. Chemoimmunotherapy

By University of Miami's 2nd Biennial Miami Leukemia Symposium FEATURING Jennifer Woyach
By University of Miami's 2nd Biennial Miami Leukemia Symposium FEATURING Jennifer Woyach
154 views
May 14, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Featured Video

19:25
Pfizer Hematology

Moving Forward in Stage III/IV Classical Hodgkin Lymphoma

Feat. A. Ip
CLL Therapy in 2019
13:16

Advances in the CLL Frontline Therapy: BTK Inhibitors vs. Chemoimmun…

University of Miami's 2nd Biennial Miami Leukemia Symposium

J. Woyach

154 views
07:09

The Big Question in CLL Frontline Therapy: How to Choose Between Ibr…

University of Miami's 2nd Biennial Miami Leukemia Symposium

J. Woyach

282 views
24:51

2020 Update on Combination Therapies in R/R CLL: Venetoclax +R, Vene…

University of Miami's 2nd Biennial Miami Leukemia Symposium

M. Davids

56 views